Author | dc.contributor.author | Río, Juan Pablo del | |
Author | dc.contributor.author | Molina, Santiago | |
Author | dc.contributor.author | Hidalgo Lanussa, Óscar | |
Author | dc.contributor.author | García Segura, Luis Miguel | |
Author | dc.contributor.author | Barreto, George E. | |
Admission date | dc.date.accessioned | 2021-03-08T21:42:01Z | |
Available date | dc.date.available | 2021-03-08T21:42:01Z | |
Publication date | dc.date.issued | 2020 | |
Cita de ítem | dc.identifier.citation | Trends in Endocrinology & Metabolism Vol. 31 (10), pp. 742-759 October 2020 | es_ES |
Identifier | dc.identifier.other | 10.1016/j.tem.2020.04.007 | |
Identifier | dc.identifier.uri | https://repositorio.uchile.cl/handle/2250/178587 | |
Abstract | dc.description.abstract | Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties. | es_ES |
Lenguage | dc.language.iso | en | es_ES |
Publisher | dc.publisher | Elsevier | es_ES |
Source | dc.source | Trends in Endocrinology & Metabolism | es_ES |
Keywords | dc.subject | Quality of life | es_ES |
Keywords | dc.subject | Healthy postmenopausal women | es_ES |
Keywords | dc.subject | Estrogen plus progestin | es_ES |
Keywords | dc.subject | Coronary heart disease | es_ES |
Keywords | dc.subject | Replacement therapy | es_ES |
Keywords | dc.subject | Double-blind | es_ES |
Keywords | dc.subject | Breast cancer | es_ES |
Keywords | dc.subject | Nitric oxide | es_ES |
Keywords | dc.subject | In Vitro | es_ES |
Keywords | dc.subject | Clinical recommendations | es_ES |
Título | dc.title | Tibolone as hormonal therapy and neuroprotective agent | es_ES |
Document type | dc.type | Artículo de revista | es_ES |
dcterms.accessRights | dcterms.accessRights | Acceso a solo metadatos | es_ES |
Cataloguer | uchile.catalogador | ctc | es_ES |
Indexation | uchile.index | Artículo de publicación ISI | |
Indexation | uchile.index | Artículo de publicación SCOPUS | |